1.13%
9.82%
-19.00%
-7.73%
82.65%
-44.58%
-88.18%
AI Spotlight on BYSI
Company Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies.The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers.
In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform.The company was founded in 2010 and is headquartered in New York, New York.
Market Data
| Last Price | 1.79 |
| Change Percentage | 1.13% |
| Open | 1.8 |
| Previous Close | 1.77 |
| Market Cap ( Millions) | 72 |
| Volume | 820 |
| Year High | 4 |
| Year Low | 0.97 |
| M A 50 | 1.69 |
| M A 200 | 2.1 |
Financial Ratios
| FCF Yield | 0.00% |
| Dividend Yield | 0.00% |
| ROE | 54.63% |
| Debt / Equity | -12.21% |
| Net Debt / EBIDTA | 28.10% |
| Price To Book | -2.32 |
| Price Earnings Ratio | -4.49 |
| Price To FCF | 0 |
| Price To sales | 38.45 |
| EV / EBITDA | -4.02 |
News
- Jan -28 - SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
- Jan -28 - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
- Nov -11 - BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
- Oct -02 - BYSI Sees Quick 5.39% Surge Amid Low Trading Volume
- Sep -16 - BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
- Sep -16 - BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
- Sep -03 - BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
- Aug -06 - SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
- May -16 - BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
- May -03 - BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
- Apr -29 - BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
- Apr -29 - BeyondSpring Files 2023 Annual Report on Form 20-F
- Mar -25 - BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
- Jan -10 - BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
- Dec -18 - BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
- Nov -07 - BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
- Oct -23 - SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
- Oct -04 - BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
- Sep -27 - BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting
- Sep -07 - BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Targeted Protein Degradation Platform
Expected Growth : 11.7 %
What the company do ?
BeyondSpring's Targeted Protein Degradation Platform utilizes small molecules to selectively degrade disease-causing proteins, offering a novel approach to treating various cancers and diseases.
Why we expect these perspectives ?
BeyondSpring's Targeted Protein Degradation Platform growth is driven by increasing adoption in oncology and rare genetic disorders, strong pipeline of novel degraders, and partnerships with pharma companies. The 11.7% growth rate is also fueled by expanding research in protein degradation, growing demand for personalized medicine, and increasing investment in biotech R&D.
Beyondspring Inc. Products
| Product Range | What is it ? |
|---|---|
| Plinabulin | A novel, intravenous (IV) chemoprotective agent that has been shown to prevent chemotherapy-induced neutropenia (CIN) and increase the survival of cancer patients |
| Siplimab | A novel, humanized monoclonal antibody that targets CD47, a key immune checkpoint receptor |
| BeyondSpring Pipeline | A pipeline of novel, clinical-stage assets that target various types of cancer, including lung, breast, and pancreatic cancer |
BeyondSpring Inc.'s Porter Forces
Threat Of Substitutes
BeyondSpring Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.
Bargaining Power Of Customers
BeyondSpring Inc. has a low bargaining power of customers due to the lack of negotiating power among patients and healthcare providers.
Bargaining Power Of Suppliers
BeyondSpring Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services.
Threat Of New Entrants
BeyondSpring Inc. has a high threat of new entrants due to the growing demand for cancer treatments and the presence of emerging biotech companies.
Intensity Of Rivalry
BeyondSpring Inc. operates in a highly competitive industry with intense rivalry among established players and emerging companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | -17.51% |
| Debt Cost | 3.95% |
| Equity Weight | 117.51% |
| Equity Cost | 5.53% |
| WACC | 5.81% |
| Leverage | -14.90% |
BeyondSpring Inc. : Quality Control
BeyondSpring Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LGND | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| YMAB | Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers … |
| ARDX | Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, … |
| APLT | Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ligand Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
BeyondSpring
A-Score
1-Year Total Return ->
🥉
Applied Therapeutics
A-Score
1-Year Total Return ->
4
Y-mAbs Therapeutics
A-Score
1-Year Total Return ->
5
Puma Biotechnology
A-Score
1-Year Total Return ->
6
